Bluejay Diagnostics (NASDAQ:BJDX) Major Shareholder Financial Lp Hrt Sells 34,938 Shares

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) major shareholder Financial Lp Hrt sold 34,938 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the transaction, the insider owned 92,055 shares of the company’s stock, valued at $128,877. The trade was a 27.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, July 9th, Financial Lp Hrt purchased 64,047 shares of Bluejay Diagnostics stock. The shares were bought at an average cost of $1.51 per share, with a total value of $96,710.97.

Bluejay Diagnostics Stock Performance

Shares of NASDAQ BJDX opened at $1.22 on Tuesday. The stock has a 50 day moving average price of $2.68 and a 200 day moving average price of $2.48. The stock has a market capitalization of $1.26 million, a PE ratio of -0.10 and a beta of 0.88. Bluejay Diagnostics, Inc. has a 52 week low of $1.03 and a 52 week high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics currently has an average rating of “Sell”.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.